Press Releases

 

LTSL/ThermoDox®

  Date Title and Summary View
Jan 18, 2017
LAWRENCEVILLE, N.J., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S Utility Patent No. 9,492,385 B2 - Temperature-Sensitive Liposomal Formulation, which is directly applicable to the method o...
Dec 16, 2016
CFDA Indicates that Positive Phase III OPTIMA Data Could Support Direct Regulatory Filing in China Expect to Initiate Additional Sites for Phase III OPTIMA Trial in Vietnam in Early 2017 LAWRENCEVILLE, N.J., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase III OPTIMA program for Therm...
Nov 30, 2016
LAWRENCEVILLE, N.J., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) for primary liver cancer (the OPTIMA Study), the study's Data Mo...
Oct 31, 2016
LAWRENCEVILLE, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study, highlighting the curative potential for ThermoDox® plus optimized radiofrequency ablation (RFA) in intermediate primary liver cancer, also know...
Oct 11, 2016
First Ever Clinical Trial in Children Using a Targeted Chemotherapeutic Drug Released by Focused Ultrasound Expected to Commence in Q4 2016  Initiation of this NIH-funded Study follows the Recent Announcement of NIH's Finding That Thermal Dose Appears to Improve Overall Survival in Primary Liver Cancer Patients Treated with ThermoDox® L...
Sep 12, 2016
Conclusions Drawn from Results of Celsion's HEAT Study Prompted NIH Analysis; Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit Compared to Treatment with RFA Alone Abstract Accepted for Oral Presentation at the 2016 RSNA Annual Meeting LAWRENCEVILLE, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) -- ...
Aug 15, 2016
Subgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox® plus Optimized RFA Data from the Chinese Cohort of Patients Show Clinically Meaningful Benefit LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion...
Aug 9, 2016
LAWRENCEVILLE, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced today that it has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement (the "Agreement") with Zhejiang Hisun Pharmaceutical Co. Ltd. (SSE Code:600267), a leading pharmace...
Apr 26, 2016
LAWRENCEVILLE, N.J., April 26, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combi...
Apr 19, 2016
LAWRENCEVILLE, N.J., April 19, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® and Doxil® was presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.  GEN-1 is an IL-12 DN...
Page:
1
... NextLast
= add release to Briefcase
Share This